Germany: No Liberalization of Public Advertising of Rx Compounds

Last Updated: 2 March 2011
Article by Florian Geyer, LL.M.

Pharmaceutical Advertising: No Liberalization of Advertising for Prescription Drugs

Pharmaceutical advertising is regulated by the Act on Advertising in the Health Care System [HWG]. Courts regularly must decide which information about prescription drugs (Rx compounds) may also be made available to consumers and the means by which Rx compounds can be advertised. Pursuant to Section 10(1) HWG, advertising outside of professional circles (physicians, dentists, veterinarians, pharmacists and person authorized to deal in such drugs) is not permitted. This year, the European Commission, accompanied by considerable interest in the sector, also took up this question.

At the end of September, the first part of the " Pharmaceutical Package," which concerned the amendment of Directive 2001/83/EC for the creation of a Community Code for Human Drugs (Community Code), was adopted in the European Parliament. It contains new regulations on the prevention of drug counterfeiting, on consumer information about Rx compounds as well as on drug safety oversight (pharmacovigilance). As was already seen in the run-up to the vote, the parliamentarians rejected the original plans of the EU Commission, a far-reaching liberalization of regulations on drug advertising. In particular, they spoke out against relaxing the advertising prohibition on prescription drugs. Acceptance by the Council of Ministers should take place shortly. The new regulations will then become effective 18 months after publication in the Official Journal.

The EU Parliament is not focusing on information coming from the pharmaceutical manufacturer, but rather through the internet portals of independent operators. In Germany, one such portal is run today by Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen [Institute for Quality and Efficiency in Healthcare] (http// Facts about products, as well as symptoms and non-medicinal treatment alternatives, are to be provided on these internet portals. As before, only information approved by the relevant authorities is to reach patients, thus either the mandatory information pursuant to Section 4 HWG (package insert, "patient information leaflet") or other information already reviewed (professional information pursuant to Section 11a of the Pharmaceutical Act [AMG]).

If companies want to prepare information in a different manner, it must again be reviewed and approved by the authorities. Moreover, in the future the most important information in the package insert must be contained in a clear and understandable manner in a "Fact Box."

With the new Directive, politics stands opposed to the tendencies seen in the last years in the jurisprudence towards liberalizing the law on medical advertising. It remains to be seen whether this jurisprudential trend will continue in light of the new directive. Below, the jurisprudence on permissible advertising for Rx compounds will be outlined and the potential consequences of the current EU legislative process delineated.

The advertising prohibition of Section 10(1) HWG for Rx compounds is aimed in particular at preventing self-medication and not influencing the physician's freedom to write prescriptions. It flanks the prescription obligation under Section 48 AMG. In order to achieve these goals, the advertising concept in medical advertising law is traditionally construed relatively broadly. In this respect, it encompasses each product- and service-related sales advertisement for prescription drugs. Pure company advertising (image advertising), which generally advertises the company's reputation and ability without reference to particular compounds, is not subject to the advertising prohibition. To draw the distinction, the overall appearance of the advertisement, for example, the design, the context of the advertising or the content, is determinative. The borders are often fluid.

If the company is not in the foreground, but a specific compound instead, the pharmaceutical manufacturer is not permitted to appeal to consumers with information about prescription medicines even if it is objective and accurate. The EU Commission has, however, acknowledged the contradiction of this advertising prohibition (also contained in the EU Community Code) as the model of the undeceived European end consumer. This led to the Commission proposal of relaxing the strict information prohibition. It was strongly curtailed in the course of the EU legislative process.

The advertising prohibition of Section 10(1) HWG was partially corrected in jurisprudence to the effect that consumers may be made aware of drug law mandatory requirements. Differentiation must be made, however, as to the ways the information reaches the consumer. Statements contained on the packaging or in the package insert, such as mechanisms of action or indications for use, are unobjectionable. Such a correction of the basic prohibition has not taken place, however, to the extent the information contains an "advertising excess." Exempted are only statements, which the manufacturer is legally obligated to make (cf. Section 11 et seqq. AMG). Any more extensive provision of information is not permitted.

The manufacturers are themselves responsible for ensuring that the statements made are not in violation of medical advertising law. If the Federal Institute for Drugs and Medicinal Products does not object to the documents attached to the approval application or has not used them as grounds for sanction, this still does not necessarily mean the authorities view them as unobjectionable from the point of view of medical advertising law.

A violation of the prohibition on public advertising can arise not only from content but also the type and means of dissemination of the information, even if it is in itself unobjectionable under the principles described above. There is broad consensus in the jurisprudence that the use of the packet insert in display windows, newspapers ads or in TV advertising is not permitted because this information confronts the consumer unsolicited. This will also remain the case in the future. The original proposals of the EU Commission to generally permit dissemination through such push-media in the interest of better consumer information are off the table.

The courts are split on the issue of whether or when the reproduction of a package or package insert on a non-password protected part of an internet page violates the advertising prohibition. Because the internet - unlike push-media - is a passive medium, reproduction of usage information and statements as to indications are considered permissible to some extent.

Thus, the Munich Higher Regional Court classifies the standby of a package insert for retrieval on an internet page whose domain includes the name of the medicine as advertising not subject to medical advertising law because those statements exactly correspond with drug law requirements and are sought out by the end consumers themselves.

Unlike in the case of print or TV advertising, the customer does not randomly come across the advertising. Because the page can be accessed only when the correct product name is entered, the advertising prohibition does not attach under an interpretation in conformance with European law.

The Hamburg Higher Regional Court, on the other hand, still views user information on the internet as advertising, because it raises interest in prescriptions and uses. It is irrelevant that the statements made available are mandatory information under drug law. When using mandatory information there would only be room for a normative correction if the information were necessarily brought to the attention of the consumer as part of the prescription process. Just as voluntary references to prescription drugs, statements on a manufacturer's web page are not made on the basis of any legal obligation.

In light of this difference of opinion, the decision in a preliminary proceeding at the European Court of Justice (ECJ) regarding the presentation of drugs on the internet is awaited even more anxiously. In a July 16, 2009 decision, the Federal Court of Justice ("FCJ") submitted to the Luxembourg justices the question whether Article 88(1)(A) of the Community Code covers public advertising for prescription drugs "if it alone contains all information that the approval authorities were presented with as part of the approval procedure and is already made available to each who acquires the compound, and the information is not presented to the interested party unsolicited, but is only made available on the internet to those who themselves makes the effort to obtain it."

Conclusion: Looking at the view favored in Strasbourg of patient information through independent internet portals, the ECJ decision is extremely topical. It will be a question of whether the ECJ views information from the manufacturer in the interest of the information need of the mature patients as being necessary in addition to the official web portals to be established pursuant to the new guidelines. If the court does not see such a new need, the information landscape will shift sharply to offers from independent providers in respect of prescription drugs on the internet.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions